And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.

Martin J. Madden net worth and biography

Martin Madden Biography and Net Worth

Director of NovoCure

Martin Madden has been a director of Novocure since 2017. Mr. Madden retired after a 30-year career at Johnson & Johnson (from 1986 to 2017), where he most recently served as Vice President of R&D for DePuy-Synthes and Vice President of Medical Device R&D Transformation from February 2016 to January 2017; as Vice President of New Product Development, Medical Devices from July 2015 to February 2016; and as Vice President of R&D for the Global Surgery Group from January 2012 to July 2015. Earlier in his career, Mr. Madden was a medical device engineer and innovator and a leader of cross-functional teams charged with incubating, developing, and launching new products. He also serves on the board of Microbot Medical Inc. Mr. Madden graduated summa cum laude with a Bachelor’s degree in Mechanical Engineering from the University of Dayton, earned a Master’s degree with honors in Mechanical Engineering from Carnegie-Mellon University, and graduated first in his class with honors from Columbia University’s M.B.A. program.

How do I contact Martin J. Madden?: The corporate mailing address for Mr. Madden and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Martin J. Madden's contact information.
Has Martin J. Madden been buying or selling shares of NovoCure?: Martin J. Madden has not been actively trading shares of NovoCure in the last ninety days. Most recently, Martin J. Madden sold 34 shares of the business's stock in a transaction on Thursday, August 5th. The shares were sold at an average price of $153.13, for a transaction totalling $5,206.42. Learn More on Martin J. Madden's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 11 times. They sold a total of 11,523 shares worth more than $193,742.47. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

Martin J. Madden Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/5/2021	Sell	34	$153.13	$5,206.42

Martin J. Madden Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $16.25

$15.90

$16.35

50 Day Range

MA: $16.72

$14.54

$19.75

2 Week Range

Now: $16.25

$10.87

$24.74

Volume

22,150 shs

Average Volume

1,302,823 shs

Market Capitalization

$1.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

The Final Frontier

From Porter & Company | Ad

Here’s the full story for you.